Tonix Pharmaceuticals posts investor deck focused on TONMYA fibromyalgia launch and pipeline updates

• Tonix highlighted commercial traction for fibromyalgia drug TONMYA, launched Nov. 17, 2025; first FDA-approved adult fibromyalgia treatment in 15+ years.
• Reported 1Q’26 net sales of $3.7 million; $5.1 million from Nov. 17, 2025 to Mar. 31, 2026.
• Disclosed ~$185.5 million cash and cash equivalents as of March 31, 2026; no debt; runway expected into early Q2’27.
• Pipeline update included TNX-4800 Lyme disease prevention adaptive Phase 2 field study planned for 1H’27 in the U.S.
• Other planned studies: TNX-1500 organ transplant rejection Phase 2 in 2H’26; TNX-2900 Prader-Willi syndrome Phase 2 in 1Q’27.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.